BARD1 breast cancer test accurately distinguishes malignant breast cancer from benign lesions.
Showing 25 of 3087
Shares in the drug development company last traded at 73 cents before the halt.
The company has a vertically integrated model incorporating a growing site, an R&D facility and a manufacturing facility.
Technegas is inhaled by patients and allows the diagnosis of multiple respiratory diseases via imaging and analytical software
The company has started manufacturing the product and plans to launch it later this year.
Non-executive director Max Johnston has acquired shares on-market valued at more than $9,000.
The deal is part of a concerted effort by the company to “unlock shareholder value” with strategic deals that open up new markets.
Bruce Gordon has acquired two batches of shares recently with a total value of almost $13,300.
Wattle is also set to become the first vertically integrated Australian organic nutritional dairy company.
The regenerative medicine company plans to further develop the treatment through partnerships with companies commercialising cancer immunotherapies.
The latest investment takes Star Bright’s total interest in the company to 19.99% of issued shares.
US-based Dennis Eck recently purchased a $1 million parcel of shares and now holds more than 5.331 million.
BetterCells is an online platform that aims to connect functional and integrative medical practitioners with people looking to improve their health.
Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents.
An MOU between the two companies targeting advanced diagnostics and analytical services for clinical trials remains in place.
The investor event starts at 3pm on the main drag of the trendy Perth suburb of Mt Lawley.
The biotechnology company is focused on its R&D program and is funded with a $1.9 million R&D loan from Paddington Street Finance Pty Ltd.
The Hong Kong-based investment company now holds a significant interest of 19.99%.
The offer was at the same price as the recent share placement to sophisticated and institutional investors for $9 million.
Three studies are the focus as the company targets chronic illnesses, including cancer, using a pipeline that includes cannabis products and probiotics.
The research note puts the value per share at 14 cents each, or 12 cents after dilutions.
Opthea Ltd will present at next week's ASX Small and Mid-Cap Conference in Sydney, highlighting its excellent 2017-18 annual report.
The company now has its services being used in a total of eight clinical trials.
Professor David Casarett and Dr Dustin Sulak add clinical expertise and depth to the board.
Arix led a $24 million share placement and will invest $14.2 million in two tranches.